All Updates

All Updates

icon
Filter
Earnings/results
Exact Science beats analysis EPS consensus; reports jump in screening revenue
Precision Medicine
Feb 21, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Precision Medicine

Precision Medicine

Feb 21, 2023

Exact Science beats analysis EPS consensus; reports jump in screening revenue

Earnings/results

  • Exact Sciences, a molecular diagnostics company, reported a net loss per share of USD 0.72 for Q4 2022, beating analysts’ expectations of USD 0.84. Revenue for the quarter grew 17% YoY to USD 553 million, also beating analyst consensus by 4.7%. Net losses for the quarter were reduced by 42% YoY to USD 127.7 million. Revenue for the full year increased by 18% YoY to USD 2.1 billion and net losses for the year declined by 25% YoY to USD 624 million. The total, cumulative number of people that tested for cancer passed 12 million for the year, including ten million with Cologuard. 

  • The increase in revenue in Q4 2022 was mainly attributed to a 45% YoY increase in screening revenue, while precision oncology revenue and Covid-19-testing revenues reported a 4% and 87% YoY decline, respectively. 

  • The gross profit margin declined to 73% in Q4 2022 in comparison to 75% in Q4 2021. Operating expenses declined 3% YoY due to lower sales and marketing expenses (down 26% YoY) which was offset by higher general administration expenses (up 8% YoY) and higher cost of sales (up 24% YoY) compared to Q4 2021. The adjusted EBITDA significantly improved to USD 4.9 million for the quarter, from a loss of USD 115 million in Q4 2021.

  • Cash and cash equivalents and marketable securities stood at USD 0.6 billion at the end of December 2022, decreasing from USD 0.7 billion in December 2021. Exact Science increased its earnings guidance for 2023, expecting revenue of USD 2.27 billion–USD 2.31 billion, implying a 9.1%–11.1% YoY increase.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.